09/09/2021 11:58
Clarín.com
Society
Updated 09/09/2021 11:58
The American pharmaceutical company Moderna launched a program to develop a single-dose vaccine that
combines a booster against the coronavirus and another against the flu
.
"Today we announce the first step of our innovative respiratory vaccine program for the development of
a single-dose vaccine that combines a booster against covid-19 and a booster against influenza,
" the company said in a statement on Thursday.
On Wednesday, the infectologist Fernando Polack had advanced in radio statements that a group of
Argentine scientists are
participating in a project to develop a triple viral vaccine against the coronavirus, influenza and the human respiratory syncytial virus.
Moderna made its announcement in a note in which it presented the advancements of its product portfolio.
In turn, the American pharmaceutical company last week delivered the first results of its clinical trials to the European health authorities for
the evaluation of
a third booster dose
, in order to obtain their authorization.
"We are pleased to have requested a conditional marketing authorization from the European Medicines Agency for our booster [vaccine] candidate at the
50 microgram dose
level,
" said the US pharmaceutical company last Friday, after requesting permission in Europe.
Moderna announced her work on a combination vaccine in a statement.
Photo: EFE.
Moderna CEO Stéphane Bancel said additional studies and analysis "show that a 50-microgram booster dose" of their vaccine
"elicits strong antibody responses against the Delta variant"
of coronavirus.
The company explained that modified the second phase of a clinical trial to include a
third dose aticovid-19
, administered "approximately" six months after the second.
In August, the United States Food and Drug Administration (FDA) began recommending the use of a third dose against COVID-19 for people with a
weakened immune system
, such as organ transplant patients, people with HIV or some cancer patients, who did not register an adequate immune response to the first two applications.
Recently, the US authorities also announced plans to begin offering
the booster dose to the general population
that has received the mRNA vaccines (Moderna and Pfizer) starting the week of September 20 for those who have received the initial two doses more ago. eight months.
That initiative, however,
has yet to be approved
by the FDA and the country's Centers for Disease Control and Prevention (CDC).
With information from EFE.
LGP
Look also
Fernando Polack announced that Argentine scientists are participating in the development of a vaccine against coronavirus, influenza and syncytial virus
Detect 6 new cases of the Delta variant of the coronavirus in Córdoba